What is Catalent?
Catalent operates as the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The company distinguishes itself through deep-scale expertise in development sciences, advanced delivery technologies, and complex multi-modality manufacturing. As a preferred CDMO partner, Catalent provides the infrastructure necessary for the successful commercialization of diverse therapeutic modalities, ranging from small molecule drugs to complex biologics and cell and gene therapies. Its market position is defined by its ability to integrate seamlessly into the R&D and supply chain processes of its clients, effectively reducing time-to-market and enhancing product efficacy for global health brands.
How much funding has Catalent raised?
Catalent has raised a total of $5.2B across 9 funding rounds:
Stock Offering
$870M
Debt
$410.1M
Stock Offering
$24.2M
Debt
$450M
Stock Offering
$387M
Debt
$1.2B
Debt
$500M
Stock Offering
$500M
Debt
$903.4M
Stock Issuance/Offering (2014): $870M with participation from Undisclosed
Debt (2016): $410.1M led by Undisclosed
Stock Issuance/Offering (2017): $24.2M supported by JPMorgan Chase, RBC Capital Markets, Morgan Stanley, and BofA Merrill Lynch
Debt (2017): $450M featuring Undisclosed
Stock Issuance/Offering (2018): $387M backed by BofA Merrill Lynch, JPMorgan Chase, RBC Capital Markets, Morgan Stanley, and Wells Fargo Securities
Debt (2019): $1.2B with participation from JPMorgan Chase Bank
Debt (2019): $500M led by Undisclosed
Stock Issuance/Offering (2020): $500M supported by JPMorgan Chase and UBS Investment Bank
Debt (2020): $903.4M featuring Undisclosed
Key Investors in Catalent
JPMorgan Chase
A leading global financial services firm providing comprehensive investment banking, commercial banking, and asset management solutions to institutional and corporate clients worldwide.
BofA Merrill Lynch
A global financial institution offering a broad spectrum of banking, investment, and risk management services to support large-scale corporate and institutional economic activity.
Morgan Stanley
A premier global financial services firm specializing in investment banking, securities, and wealth management for corporations, governments, and institutional investors.
What's next for Catalent?
Looking ahead, Catalent is strategically positioned to capitalize on the increasing complexity of the pharmaceutical pipeline. The recent influx of capital is expected to be deployed toward the expansion of its global manufacturing network and the integration of next-generation delivery technologies. By prioritizing investment in high-growth areas such as biologics and personalized medicine, Catalent aims to reinforce its status as an indispensable pillar of the global healthcare infrastructure. The company's focus remains on scaling its operational capacity to accommodate the rising demand for specialized manufacturing services, ensuring that it remains at the forefront of medical innovation and supply chain resilience.
See full Catalent company page
